Posts Tagged 'Actos cancer'

Actos doubles bladder cancer risk, British study finds

A new study has confirmed that the diabetes medication Actos doubles the risk of developing bladder cancer among people who use the drug for at least two years. The Canadian study was published in the British Medical Journal (BMJ) and included more than 115,000 diabetes patients that were treated between 1988 and 2009.

Read more about Actos and bladder cancer…

Actos maker hid safety info from FDA, whistleblower lawsuit claims

A whistleblower lawsuit alleges that the manufacturer of the diabetes drug Actos misrepresented and hid safety information from the Food and Drug Administration. Helen Ge claims in her Actos lawsuit that Takeda Pharmaceuticals directed its staff to not classify non-hospitalized or non-fatal cases of congestive heart failure in Actos patients as serious.

Click here to read more…

FDA issues warning about Actos-bladder cancer link

The Food and Drug Administration has issued a warning that the diabetes drug Actos may increase a patient’s risk of developing bladder cancer. The agency stated that it plans to update the patient medication guide for Actos in order to alert patients that they may be at risk of developing bladder cancer by using the drug.

Click here to read more…

FDA issues Actos bladder cancer warning

The Food and Drug Administration has warned that some patients taking Actos may face an increase risk of developing bladder cancer. Actos became the world’s best selling diabetes drug after the FDA issued a previous warning about the cardiovascular side effects of Avandia.

Click here to read more…


Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 437 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.